BioAsset

Insights / All articles

Research

All Eyes On Cancer Therapy

By Sharath Venkatesan, Research Analyst at BioAsset · 1 slide

The 2026 ASCO Annual Meeting opened last Friday in Chicago. The cancer-drug data unveiled over its four days had the potential to reshape treatment standards and move billions in market value, as investors bet on the next wave of oncology winners.

The spotlight was on Revolution Medicines’ pipeline and on bispecific antibodies, a fast-emerging class of drugs that block multiple disease pathways at once. The readouts from the meeting may determine which companies pull ahead in the race to define the future of cancer therapy.

This article is the text version of a BioAsset slide post. See the original slides on bioasset.info.